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Abstract
Background: Excessive wound healing, with scarring of the episcleral tissue or encapsulation of the filtering bleb is
the main reason for failure in trabeculectomy. Ranibizumab, an inhibitor of the Vascular Endothelial Growth Factor
(VEGF), is seen as a promising candidate to prevent or treat extensive wound healing. We describe the design of a
two phased study, i) assessing the local tolerability and safety of topical ranibizumab and ii) assessing the efficacy
of topical ranibizumab against placebo in patients who underwent trabeculectomy with mitomycin C combined
with phacoemulsification and intra ocular lens (IOL) implantation.
Methods/Design: In the first phase five patients that had trabeculectomy with mitomycin C combined with
phacoemulsification and IOL implantation will be treated with topical ranibizumab (Lucentis
®) eye drops (2 mg/ml)
four times daily for one month. The treatment will be started at the first postoperative day. Patients will be
assessed for local and systemic side effects using a standardised schedule. In the second phase, after successful
completion of phase 1, consenting eligible patients who underwent trabeculectomy with mitomycin C combined
with phacoemulsification and IOL implantation will be randomised to either receive topical ranibizumab eye drops
(2 mg/ml) four times daily for 1 month or placebo (BSS 4x/d for 1 month). Patients will be reviewed weekly for 4
weeks until conjunctival sutures are removed. Further follow up examinations are planned after 3 and six months.
Assessment of differences in the intraocular eye pressure will be considered primary, and bleb appearance/
vascularisation using a standardized photography and the Moorfields bleb grading system, postoperative
intraocular pressure and conjunctival wound healing problems will be considered secondary outcome parameters.
Discussion: Anti-VEGF-antibodies might be more effective in preventing scaring and might have fewer toxic side
effects than the currently used anti-metabolites and may replace them in the long term.
Trial Registration: ISRCTN: ISRCTN12125882
Background
Trabeculectomy is a surgical procedure for glaucoma, in
which a guarded fistula is created. This fistula allows
aqueous humour to drain from the anterior chamber to
the subconjunctival space providing a controlled lower-
ing of the intraocular pressure (IOP). The intervention
was first described 1968 by Cairns [1]. Today it is the
most commonly performed surgical intervention for
patients with glaucoma who are not sufficiently con-
trolled with medication or laser treatment alone.
An increased wound healing response with scarring of
the episcleral tissue or encapsulation of the filtering bleb
is the main reason for failure of filtration surgery with
consecutive loss of IOP control. To enhance the success
rate of filtration surgery, wound healing modifying
agents, such as 5-fluorouracil or mitomycin C (MMC)
are widely used [2-7].
However, severe side effects from these drugs to the
surface tissue of the eye are observed regularly. Especially
corneal epithelial toxicity is reported as complication of
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tion, after the use of MMC thin walled, largely hypocellu-
lar and avascular drainage blebs increase the risk of
wound leak with consecutive hypotension and bleb infec-
tion. A T-lymphocyte mediated lysis of MMC treated
Tenon’s capsule fibroblasts could be responsible for this
problem [9].
As postoperative bleb vascularisation and tortuosity of
the present blood vessels are associated with scarring of
the filtering bleb recently available anti-VEGF-antibodies
could be an alternative to known antiproliferative agents
[10]. Anti-VEGF-antibodies may have a more precise
effect in modulating the wound healing processes than
anti metabolites and additionally may cause fewer side
effects [11].
Anti-VEGF-antibodies
Vascular endothelial growth factor (VEGF) was first
described as a molecule that increases the permeability
of blood vessels. Additionally VEGF promotes the prolif-
eration of new blood vessels. The growth factor is essen-
tial for normal embryonic development and wound
healing. In conditions with neovascularisation and in
malignant tumors VEGF is overexpressed. At least 6 iso-
forms of this molecule are expressed in humans.
In wound healing cell-mediators and growth factors
such as VEGF play a central role. As soon as the bal-
ance of these growth factors is disturbed, altered
wound-healing processes with extensive scar formation
can occur. For example keloids show an increased den-
sity of blood vessels compared to normal scar tissue. In
vitro experiments demonstrated an overexpression of
TFG-beta and VEGF from keloid fibroblasts [12]. It was
also shown, that dexamethasone induces keloid regres-
sion by suppressing endogenous VEGF expression and
fibroblast proliferation [13].
A similar type of pathologic wound healing process
could be responsible for the bleb encapsulation after tra-
beculectomy. Following trabeculectomy bleb failure
occurs due to massive inflammatory vascularisation of
the conjunctiva with associated migration of fibroblasts.
Without the treatment of antimetabolites, such as
MMC, this process may lead to scar formation [6]. This
reaction might be triggered by several factors such as
surgical trauma, the presence of aqueous humour or
previous topical medication. It was shown that cultured
conjunctival fibroblasts could be stimulated to produce
VEGF by pro inflammatory cytokines [14].
The effect of angiogenesis inhibitors on Tenon’s
capsule fibroblasts has been described in the past and it
was shown an inhibitory effect of proliferation and
migration [15]. Based on these findings it is imaginable
that a selective inhibition of growth factors such as
VEGF could be an approach to prevent or treat
extensive wound healing. Different anti-VEGF-antibodies
are used to treat pathologic conditions with over expres-
sion of VEGF. They differ in molecule size and binding
site at the growth factor, which determines if all
isoformes of VEGF are inactivated.
Currently, two therapeutic Anti-VEGF-antibodies
exist; bevacizumab and ranibizumab. Bevacizumab is
used in combination with intravenous 5-fluorouracil-
based chemotherapy and indicated for first-line treat-
ment of patients with metastatic carcinoma of the colon
and rectum. Due to its inhibiting effect of angiogenesis,
Patients undergoing surgery during bevacizumab therapy
are at an increased risk of wound healing complications
[16,17]. The use of bevacizumab to treat a failing
filtering bleb in addition to a needling procedure has
been described in one single patient [18]. In addition,
topical bevacizumab has been used to treat corneal
neovascularisation [19]
At the moment there is one trial planned to compare
the effectiveness of MMC to ranibizumab in patients
undergoing filtration surgery for glaucoma (Michael J
Pro, Wills Eye Institute). In this study it is planned to
inject ranibizumab into the subtenon’s space once dur-
ing the initial surgery. The disadvantage of this form of
application is the short half life time of the drug. In our
opinion, this form of application does not cover the
main peak of scarring reaction that is occurring around
2-3 weeks after surgery. The advantage of a topical
application for 4 weeks is a continuous drug level during
this critical phase.
Bevacizumab has been used already in ophthalmology
to treat subretinal neovascularisation in AMD and
neovascular glaucoma [20,21]. By an intravitreal use of
the drug no toxic side effects to the retina were observed
in an animal model [22].
Ranibizumab is a fully humanized monoclonal
antibody-fragment and therefore has a low molecular
weight, which results in good tissue penetration. The
antibody inactivates all isoforms of VEGF-A. Ranibizu-
mab is used for the treatment of subretinal choroidal
neovascularisation and injected in the vitreous [23]. The
maximum tolerated single intravitreal dose of ranibizu-
mab was 500 μg [24]. Ranibizumab has a short systemic
half-life (12 hours) and a long intravitreal half-life
(6 days) [25].
Clinical safety summary
For the intravitreal use a monthly dose of 500 μgo f
ranibizumab (one single injection) was shown to be
safe. With higher doses a significant intraocular
inflammation was observed [24]. It is not expected that
topically applied ranibizumab reaches the same intrao-
cular concentrations as if it is injected directly into the
vitreous.
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able reflux of the injected drug into the subconjunctival
space is observed. Even in these cases, where relatively
high concentrations of the drug are reached in the sub-
conjunctival space, no local or systemic side effects were
observed in clinical practice.
In clinical use, topical bevacizumab has been used
safely in a concentration of up to 10 mg/ml. No sys-
temic or local side effects such as uveitis have been
observed up till now.
In summary, there are no data about topical applied
ranibizumab so far. However, the serum half-life time is
short (six times shorter than in the vitreous) and the
administered topical dose low. These data suggest that
topical applied ranibizumab has a good safety and toler-
ability profile.
When anti-VEGF drugs are used systemically (bevaci-
zumab), side effects such as gastrointestinal perforations,
fistulas, arterial hypertension, proteinuria, arterial and
venous thromboembolic events, wound healing
problems, tumour associated bleeding and encephalopa-
thy have been observed. However, compared to the topi-
cal application, which is planned in this study, much
higher drug concentrations are used in systemic use of
bevacizumab.
Objectives
The primary objectives of the study are:
- Assessment of local tolerability and safety of topi-
cal ranibizumab
- Assessment of efficacy of topical ranibizumab in
patients undergoing trabeculectomy with MMC for
medically uncontrolled glaucoma.
Methods/Design
Ethics
Before initiating this study, the protocol, the informed
consent form and any other written information to be
given to patients was reviewed and approved by the
Ethics Committee of the Lucerne Cantonal Hospital.
The study will be carried out in compliance with the
protocol and the declaration of Helsinki, concerning
medical research in humans. The investigator will
explain to each patient the nature for the study, its pur-
pose, the procedures involved, the expected duration,
the potential risks and benefits involved and any dis-
comfort it may cause. Each patient must be informed
that participation is voluntary, that he or she may with-
draw from the study at any time and without giving a
reason. The Withdrawal will not affect the subsequent
medical treatment or relationship with the treating
surgeon.
Setting
Eye Clinic, Cantonal Hospital of Lucerne
Study design Phase 1 (case series)
In this first step, the local and systemic safety of the
topical application of Lucentis
® will be assessed. There-
fore a number of 5 patients that have had trabeculect-
omy with MMC combined with phacoemulsification and
IOL implantation will be treated with topical ranibizu-
mab eye drops (2 mg/ml) four times daily for one
month. The treatment will be s t a r t e da tt h ef i r s tp o s t -
operative day. The patients will be assessed carefully for
local and systemic side effects using the following
schedule. (See Figure 1)
Local side effects (conjunctival inflammation, wound
healing problems, anterior chamber inflammation). Slit
lamp examinations will be performed by an ophthalmic
surgeon.
Daily eye examination and assessment of the ante-
rior chamber inflammation using a laser flare meter
during the first week (patients routinely stay in the
ward for the first week). The eye examination at
baseline and each follow up visit consists of best cor-
rected visual acuity, intraocular pressure using Gold-
man applanation tonometry, non dilated slit lamp
examination with assessment of conjunctival and
intraocular inflammation, filtering bleb morphology,
size and function and filtering bleb leaks.
The same examinations will be repeated on a weekly
schedule for the first month and after two months
time.
At day 1,7,14,21 and 28 a slit lamp photography will
be taken.
Systemic side effects (elevated blood pressure, protei-
nuria, thromboembolic events, and gastrointestinal per-
foration)
Vital signs (systemic blood pressure) will be exam-
ined daily during the first week, then weekly during
the first months and after two months time. The
examination will be done by a nurse while the
patient is on the ward and at every follow up visit.
An examination of the urine for proteinuria will be
performed at day one (baseline), at day 7, 14, 21 and
28 and after 2 months time.
The examination of the vital signs and the urine will
be performed while the patient stays on the ward
ant at the routine follow up visits prior to the eye
examination.
Patients will be asked during the follow up visits by
an ophthalmic surgeon to report any systemic side
effect, especially thromboembolic events and
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side effect will be documented.
Study design Phase 2 (randomised controlled trial RCT)
In this prospective, randomised controlled study we will
include patients who underwent trabeculectomy with
MMC combined with phacoemulsification and IOL
implantation.
Topical ranibizumab eye drops (2 mg/ml) four times
daily for 1 month will be compared with placebo.
At the first postoperative day after the trabeculect-
omy or the phaco-trabeculectomy patients will be eval-
uated. After the inclusion criteria have been fulfilled
patient will be allocated to the treatment (Ranibizumab
2 mg/ml 4x/d for 1 month) or the placebo group (BSS
4x/d for 1 month). In addition, all patients will receive
the standard treatment (dexamethasone 0.1% eye drops
hourly, Floxal SDU TID and scopolamin eyedrops
BID).
Treatment allocation will be performed in a rando-
mised fashion using an Excel-based random generator.
To attain concealment of treatment allocation, the ran-
dom sequence will be kept at the hospital pharmacy
(pharmacy controlled randomisation). At study entry,
the treating physician will call the randomisation centre
and will receive the allocated treatment and study id
after providing patient details.
Patients and physicians will be blinded to treatment
allocation. Unblinding will be performed after the last
follow up visit 6 months after inclusion of the last study
patient.
Day -1     Glaucoma patients scheduled for phaco-trabeculectomy 
- Baseline examination (routine examination for any scheduled patient) 
   -  Eligibility  assessment 
   -   C o n s e n t  
   -   S t u d y   i n c l u s i o n  
      - Baseline Tests (Vital signs, urine test for proteinuria, slit lamp- 
       examination,  flare  meter  measurement) 
Day  0    Surgery  (phaco-trabeculectomy) 
Day 1      definitive study inclusion, start of treatment 
   Treatment  Examinations    
      Vital signs  Urine  Slit lamp  Photo  AC Flare  Interview 
Day 1  x  x  x  x  x  x  x 
Day 2  x  x     x     x  x 
Day 3  x  x     x     x  x 
Day 4  x  x     x     x  x 
Day 5  x  x     x     x  x 
Day 6  x  x     x     x  x 
Week 1  x  x  x  x  x  x  x 
Week 2  x  x  x  x  x  x  x 
Week 3  x  x  x  x  x  x  x 
Month  1 x  x  x x x x  x 
Month 2     x  x  x  x  x  x 
Figure 1 The study design of phase 1.
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junctival sutures are removed (normal schedule). Further
follow up examinations are planned after 3 and six
months.
No treatment that is indicated to maintain bleb func-
tion will be withheld (Laser suturolysis, removal of
sutures, use of tissue plasminogen activator etc.).
Patients will be followed up weekly for 4 weeks until
conjunctival sutures are removed. Another follow up
examination is then planned after one, 3, and 6 month.
(See Figure 2)
Patients will undergo a careful eye examination at
baseline and each follow up visits. The eye examination
consists of best corrected visual acuity, intraocular pres-
sure using Goldman applanation tonometry, non dilated
slit lamp examination with assessment of conjunctival
and intraocular inflammation, filtering bleb morphology,
size and function and filtering bleb leaks. The findings
will be documented using slit lamp photography. The
appearance of the filtering bleb will be graded using the
Moorfields bleb grading system (vascularity, size,
height).
Interventions to maintain bleb function will be
documented.
Participants/Population
Inclusion Criteria
Patients with primary open angle glaucoma (POAG),
PEX and pigment dispersion Glaucoma of at least 18
years of age, with no previous intraocular surgery under-
going trabeculectomy or phaco-trabeculectomy will be
included in this study.
Exclusion Criteria
Patients with primary angle closure glaucoma
(PACG)
Glaucoma due to other causes
Day -1     Glaucoma patients scheduled for phaco-trabeculectomy 
- Baseline examination (routine examination for any scheduled patient)
Day  0    Surgery  (phaco-trabeculectomy) 
Day  1    -  Eligibility  assessment 
   -   C o n s e n t  
   -   S t u d y   i n c l u s i o n  
      - Allocation to treatment or placebo group 
      - Baseline Tests (Slit lamp photography, flare meter measurement) 
   -  Start  of  treatment 
   Treatment  Examinations 
      IOP  Slit lamp  Photo  AC Flare  Interview 
Day  1  x x x  x  x  x 
Week  1  x x x  x  x  x 
Week  2  x x x  x  x  x 
Week  3  x x x  x  x  x 
Month  1  x x x  x  x  x 
Month 3     x  x  x  x  x 
Month 6     x  x  x  x  x 
Figure 2 The study design of phase 2.
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Any surgery during the last 3 months
Patients with uveitis or inflammatory ocular surface
disease
Patients with single eyes
Patients presenting the first postoperative day with
bleb leak, hypotension or situations that potentially
need another surgery are not eligible
Pregnant and breast feeding women are excluded
from the study.
Women planning to get pregnant will be excluded
from the study too
Investigational and reference therapy
Considerations about topical application and duration of
treatment
For the intravitreal use a monthly dose of 500 μgo f
ranibizumab (one single injection) was shown to be
safe. With higher doses a significant intraocular
inflammation was observed [24]. It is not expected that
topically applied ranibizumab reaches the same intrao-
cular concentrations as if it is injected directly into the
vitreous.
Topical Bevacizumab has been used safely in a con-
centration of 10 mg/ml. No side effects such as uveitis
have been observed up till now.
The half-life time of the drug in serum is 6 times
shorter than in the vitreous (12 hours vs. 3 days) [25].
We presume that the tissue penetration is sufficient to
reach the whole ocular surface tissue (conjunctival
epithelium, lamina propria, tenon)
As increased bleb vascularisation occurs early post-
operative and encapsulation of filtering blebs is observed
after 2-4 weeks postoperative [26], in our opinion, dura-
tion of treatment of 4 weeks is sufficient.
Preparation of drug
Ranibizumab vials (10 mg/ml) customized for AMD
patients will be used to prepare the eye-drops. The drug
will be provided by Novartis.
Ranibizumab will be used in the concentration of
2 mg/ml (dilution of the original ranibizumab solution
(10 mg/ml) 1:4).
O n es i n g l ed r o po ft h ef i n a ls o l u t i o nh a sav o l u m eo f
0.040 ml and will provide 80 μg of ranibizumab. (Daily
dose 320 μg = 4 drops per day)
The drug will be prepared by the hospital pharmacy.
The original formulation of Lucentis
® will be diluted
using BSS (balanced salt solution. A total amount of 28
vials (one1 ml syringe containing 250 μlo ft h es o l u t i o n
for every day) will be handed to the patient. A total
volume of 7 ml will be handed to the patient. The drug
has to be stored in the fridge (5°C).
Evaluation criteria
Phase 1
Primary outcome measure: Local conjunctival inflamma-
tion, wound healing problems, anterior chamber inflam-
mation, systemic adverse effects (i.e. elevated blood
pressure, proteinuria, thromboembolic events, and
gastrointestinal perforation)
Phase 2
Primary outcome measure:
Difference in intraocular pressure (IOP) between
groups: An IOP < 16 mmHg without additional topi-
cal antiglaucomatous therapy as cut off point.
Secondary outcome measure:
Bleb appearance/vascularisation assessed using
standardized photography and the Moorfields bleb
grading system.
In addition, eyes will be carefully assessed regarding
to conjunctival wound healing problems and other
local side effects such as intraocular inflammation
(anterior chamber flare measured using a flare
meter)
Number of additional interventions to maintain bleb
function or to treat complications (bleb leak)
Number of additional medications to maintain
pressure control
Statistics
Phase I
Descriptive statistics will be used to analyse the resulting
IOP and flare meter measurements at different time
points.
Phase II
Baseline data from the treatment and the placebo group
will be described in standard fashion.
IOP comparisons between the two groups will be
performed using the t-test or the non-parametric
Wilcoxon-Mann-Whitney-Test if appropriate. P values
of < 0.05 will be considered statistically significant.
Kaplan-Meyer curves for bleb survival for each group
and a scatter plot with pre and postoperative IOP will
be drawn. Regression analyses, entering the difference in
IOP as the dependent variable treatment allocation and
all variates of which baseline imbalances of at least
10 percent occurred as independent variates will be
performed to counteract residual confounding.
Statistical analyses will be based on the intention to
treat principle.
Sample size considerations
For a two sided test at 80% power and alpha value of
0.05, the sample size required to detect a 4 mmHg
Bochmann et al. BMC Ophthalmology 2011, 11:1
http://www.biomedcentral.com/1471-2415/11/1
Page 6 of 9difference in IOP (assuming standard deviation of
5 mmHg) is 25 per group. Therefore we will enrol a
total of 50 patients.
Removal of patients from therapy or assessment
It will be documented whether or not each patient
completed the study. If for any patient either study
treatment or observations are discontinued, the reason
will be recorded.
Reasons for which a patient may discontinue partici-
pation in a study may include one of the following:
Adverse events (moderate or severe)
Abnormal laboratory values
Abnormal test results
Protocol violation
Patient withdrew consent
Lost to follow-up
Patients have the right to withdraw from the study at
a n yt i m ef o ra n yr e a s o n ,w i t h o u tt h en e e dt oj u s t i f y
their decision. The investigator also has the right to
withdraw patients in case of safety issues or protocol
deviations. In case of patient withdrawal, the investigator
will attempt to perform all protocol-defined end of
study assessments and document the main reason for
withdrawal in the case report form (if known).
For Phase I, patients that discontinue the study will be
replaced (unless withdrawal was for safety reasons). For
Phase II, patients that discontinue the study will not be
replaced. The number of calculated patients (sample
size) is large and it is probably not feasible to recruit a
significant larger number of patients within a reasonable
period of time. If the study period is too long there
might be problems to get consistent result from the sur-
gical procedure.
Compliance control and drug accountability
Records of study medication used, dosages administered,
and intervals between visits will be kept during the
study. The investigator maintains an accurate record of
the shipment and dispensing of study drug in a drug
accountability ledger. Monitoring of drug accountability
will be performed during site visits and at the comple-
tion of the trial. Patients will be asked to return all
unused study drug and packaging at the end of the
study or at the time of study drug discontinuation.
Pregnancy test and contraception during the study
Pregnant or breast-feeding women or women of child-
bearing potential and their partners, refusing to use two
reliable methods of contraception (including 1 barrier
method) during the study will be excluded. Prior to study
inclusion, a serum pregnancy test (HCG + ß-chain) will
be performed in all not postmenopausal or permanently
sterilised women.
Acceptable forms of effective contraception are:
1) Primary forms of contraception include intrauter-
ine devices, oral contraceptive agents that the patient
has already been using for at least 90 days before
screening, and injectable/implantable/insertable hor-
monal birth control products.
2) Secondary forms of contraception include dia-
phragms, latex condoms and cervical caps.
In case of a pregnancy during the study period extra
follow up examinations will be planned to assess the
course of the pregnancy.
Safety issues/adverse events
An adverse event is defined as any untoward medical
occurrence in a patient or clinical investigation subject
administered a pharmaceutical product and which
does not necessarily have a causal relationship with
this treatment. An adverse event can therefore be any
unfavourable and unintended sign, symptom or dis-
ease temporally associated with the use of an investi-
gational medical product whether or not related to
the drug.
Adverse events and adverse drug reactions will be
documented in the Case Report Form. Information
about serious adverse events (resulting in death, life-
threatening conditions or hospitalisation) will be col-
lected and recorded in the Case Report Form and
reported to the investigator/sponsor within 24 hours.
All adverse events will be collected by the investiga-
tors responsible for the study.
Adverse events will be reported spontaneously by
the patients, observed by the investigator during the
follow up visits or elicited by a non-leading question.
All adverse events will be documented in the Case
report form.
Adverse events will be recorded form signed
informed consent until the last follow up visit (end
of study)
Information about all adverse events, whether volun-
teered by the patient, discovered by investigator
questioning or detected through physical examina-
tion or laboratory tests will be collected and
recorded.
The intensity of an adverse event will be rated as
follows:
mild (Awareness of signs or symptoms, no dis-
ruption of usual activity)
moderate (Event sufficient to affect usual activity
(disturbing))
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(unacceptable))
Causality assessment
An adverse event is related to the study drug if the
investigator judges it causally related. The causal rela-
tionship will be rated as follows:
Reasonably possibility
Unclear
No reasonable possibility (Adverse event due to the
disease under study, pre-existing
Medical conditions, study drug withdrawal effect)
Reporting of adverse events
All adverse events will be reported in the final study
report
In case of serious adverse event the study will be
stopped and a change of the protocol will be considered.
A suspected unexpected serious adverse drug reaction
(SUSAR) (A serious adverse reaction, the nature or
severity of which is not consistent with the applicable
product information) will undergo immediate unblind-
ing and expedited reporting using the CIOMS-form as
soon as possible (maximum 7 days when resulting in
death or life threatening condition, 14 days in all other
cases) to the regulatory authority (Swissmedic).
An annual safety report will be submitted to
Swissmedic.
Potential hazards
It is anticipated that there should be no hazards from
the study to either the patient or researcher.
Drug & Costs
The project does not involve using any new equipment,
material or skill not already available in the Department
of Ophthalmology. 155 vials of the original formulation
of ranibizumab will be provided by Norvartis
Compensation
There will be no special compensation arrangements.
Quality control and data quality assurance procedures
A monitor will supervise the study and will verify the
adherence to the protocol, the maintenance of the
study-related records ant the completeness and accuracy
of all Case Report Form entries compared to the source
data. The investigator will co-operate with the monitor
to ensure that any discrepancies that may be identified
are resolved.
The monitor is a fully trained ophthalmologist from
the eye clinic and has a certificate in good clinical
practice. Surgical interventions will be performed by
one fellowship trained, ophthalmic surgeon. Fully
trained ophthalmic specialists will perform the follow
up visits. The investigator and all co-investigators
have attended a course in good clinical practice and
are certified. The hospital pharmacy that will perform
randomisation and prepare the study drug is fully
approved. To ensure the collection of accurate, com-
plete and reliable data, training sessions for the co-
investigators and monthly investigator meetings will
be held.
Direct access to source data and documents
The investigator institution (Eye Clinic Lucerne) will
retain all medical records and documents from the
study for the time required by national regulations.
The investigators institution will permit trial related
monitoring, audits, independent Ethics Committee and
Institutional Review Board reviews by the government
regulatory authorities (Swissmedic) providing direct
access to source data and documents. The sponsor of
the study drug, namely Novartis has no access to origi-
nal medical records. Novartis and its agents will have
access to anonymised copies of medical records and
Case Report Forms only.
Missing data and dropouts
As data will be collected during the routinely performed
follow up visits after a surgical intervention we do not
expect a significant number of dropouts.
Patients with missing data will be included in the
study but missing values will not be substituted. Prior to
unmasking of the patients a review of the data will be
performed and patients with major protocol deviations
such as deviation from inclusion and exclusion criteria
or deviation from the treatment and dosing schedule
will be excluded.
Conclusion
Vascularised filtering blebs are associated with a poor
prognosis. In addition to reducing bleb neovascularisa-
tion, angiogenesis inhibitors may have an additional
potential in modulating fibroblast activity. Anti-VEGF-
antibodies might be more effective in preventing scaring
and might have fewer toxic side effects than the cur-
rently used anti-metabolites and may replace them in
the long term.
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